Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1995; 74(01): 515-520DOI: 10.1055/s-0038-1642731 Symposium Clinical Coagulation Laboratory and Oral Anticoagulation Therapy Treatment Schattauer GmbH Stuttgart Quality Control and Oral Anticoagulation F E Preston Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (439 kb) References References 1 Poller L, Thomson JM. The Manchester comparative reagent. In Human Blood Coagulation. Hemker HC, Loelinger EA. Veltkamp eds Springer; New York: 1969. pp 290-295 2 Zucker S, Cathey MH, Sox PJ, Paul EC. Standardization of laboratory tests for controlling anticoagulant therapy. Am J Path 1970; 53: 348-354 3 Bailey EL, Harper TA, Pinkerton PH. Therapeutic range of 1-stage prothrombin time in control of anticoagulant therapy. CMAJ 1971; 94 4 Hirsh J, Deykin D, Poller L. “Therapeutic range” for oral anticoagulant therapy. Chest 1989; 2 Suppl llS-15S 5 Poller L, Tabemer DA. Dosage and control of oral anticoagulants, an international survey. Br J Haem 1982; 51: 479-485 6 Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants. Lancet 1954; 92-97 7 Poller L. INR and the therapeutic range. Biologia and Clinica Haematologica 1987; 9: 203-213 8 Lewis SM. Annotation Thromboplastin and oral anticoagulant control. B J Haem 1987; 66: 1-4 9 van den Besselaar AMHP, Bertina RM. Hierarchy of reference thromboplastins. B J Haem 1994; 88: 223-224 10 Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haem 1983; 49: 238-244 11 Kirkwood TBL, Lewis SM. Requirements for thromboplastins and plasmas used to control oral anticoagulant therapy. WHO Technical Report Series 1983; 687: 81-99 12 Kitchen S, Walker ID, Woods TAL, Preston FE. Thomboplastin related differences in the determination of international normalised ratio: A cause for concern. Thromb Haemostas 1994; 72: 426-429 13 Collins RC, Phillips WS, Makris M, Preston FE. 1995 to be submitted 14 Poller L, Tabemer DA, Thomson JM, Morris J, Mibasham RF, Shinton NK. Effect of the choice of WHO international reference preparation for thromboplastin on INR. J Clin Path 1983; 46: 64-66 15 van den Bessalaar AMHP, Lewis SM, Mannucci PM, Poller L. On behalf of the subcommittee. Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. Thromb Haemostas 1993; 69: 85 16 Thomson JM, Tabemer DA, Poller L. Automation and prothrombin time: A United Kingdom field study of two widely used coagulo- meters. J Clin Path 1990; 43: 679-684 17 van den Besselaar AMHP, Bertina RM. Multi-center calibration of the secondary reference material for thromboplastin, rabbit, plain, coded, CRM149R. Thromb Haemostas 1991; 65: 263-267 18 Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-320 19 Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemostas 1993; 69: 236-240 20 Phillips WS, Collin RC, Makris M, Preston FE. To be submitted 21 Poller L. The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Brit J Haem 1994; 86: 112-117
